| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 5 | +80.00% | -6.67% | -1.16% | -5.50% | -7.19% | — |
| 14d | 5 | +60.00% | -3.58% | +0.54% | -4.13% | -6.33% | — |
| 30d | 5 | +80.00% | -0.24% | -0.19% | -0.05% | -4.28% | — |
| 60d | 5 | +40.00% | +8.49% | +3.19% | +5.29% | +2.43% | — |
| 90d | 5 | +60.00% | +6.16% | +0.80% | +5.36% | +4.60% | — |
| 180d | 5 | +40.00% | +1.57% | +6.35% | -4.78% | -7.23% | — |
| 1y | 5(1 pending) | +75.00% | -2.09% | +15.78% | -17.87% | -19.99% | — |
| 2y | 5(5 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 240,000 | — | — | 240,000 | Jan 2, 2026 | Jan 5, 2026 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE Chief Operating Officer | 21,828 | — | — | 0 | Nov 13, 2025 | Nov 14, 2025 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASE Chief Operating Officer | 21,828 | $0.64 | $14.0K | 32,617 | Nov 13, 2025 | Nov 14, 2025 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE Chief Operating Officer | 21,828 | $8.71 | $190.0K | 10,789 | Nov 13, 2025 | Nov 14, 2025 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 261,900 | — | — | 261,900 | Jan 2, 2025 | Jan 3, 2025 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE Chief Operating Officer | 25,000 | — | — | 21,828 | Dec 12, 2024 | Dec 13, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASE Chief Operating Officer | 25,000 | $0.64 | $16.0K | 31,024 | Dec 12, 2024 | Dec 13, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 25,000 | $12.30 | $307.4K | 6,024 | Dec 12, 2024 | Dec 13, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE Chief Operating Officer | 15,000 | — | — | 46,828 | Dec 11, 2024 | Dec 13, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASE Chief Operating Officer | 15,000 | $0.64 | $9.6K | 21,024 | Dec 11, 2024 | Dec 13, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 15,000 | $12.43 | $186.4K | 6,024 | Dec 11, 2024 | Dec 13, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 50,000 | $15.00 | $750.0K | 6,024 | Aug 20, 2024 | Aug 21, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASE Chief Operating Officer | 50,000 | $0.64 | $32.0K | 56,024 | Aug 20, 2024 | Aug 21, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE Chief Operating Officer | 50,000 | — | — | 61,828 | Aug 20, 2024 | Aug 21, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASE Chief Operating Officer | 30,000 | $0.64 | $19.2K | 36,024 | Aug 13, 2024 | Aug 15, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE10b5-1 10b5-1 plan | 30,000 | $13.00 | $390.0K | 6,024 | Aug 13, 2024 | Aug 15, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | SALE Chief Operating Officer | 30,000 | — | — | 111,828 | Aug 13, 2024 | Aug 15, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 350,000 | — | — | 350,000 | Jan 2, 2024 | Jan 4, 2024 ↗ | View → |
| SPRY ARS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 145,000 | — | — | 145,000 | Jan 3, 2023 | Jan 5, 2023 ↗ | View → |